I-Mab Announces Acquisition of Hong Kong Subsidiary
Ticker: NBP · Form: 6-K · Filed: Oct 28, 2025 · CIK: 1778016
| Field | Detail |
|---|---|
| Company | I-Mab (NBP) |
| Form Type | 6-K |
| Filed Date | Oct 28, 2025 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 2 min |
| Key Dollar Amounts | $1.8 million, $1.2 million, $3.875 m |
| Sentiment | neutral |
Sentiment: neutral
Topics: acquisition, subsidiary, restructuring
TL;DR
I-Mab's HK subsidiary got bought, details scarce.
AI Summary
On October 28, 2025, I-Mab announced the closing of a transaction where its wholly owned subsidiary, I-Mab Biopharma Hong Kong Limited, was acquired. The filing does not specify the terms or value of this acquisition.
Why It Matters
This filing indicates a corporate restructuring or divestiture by I-Mab, which could impact its operational structure and future strategic direction.
Risk Assessment
Risk Level: medium — The lack of specific details regarding the transaction's terms and financial impact introduces uncertainty.
Key Players & Entities
- I-Mab (company) — Filing company
- I-Mab Biopharma Hong Kong Limited (company) — Wholly owned subsidiary being acquired
FAQ
What was the closing date of the transaction?
The transaction closed on October 28, 2025.
Which subsidiary of I-Mab was involved in this transaction?
I-Mab Biopharma Hong Kong Limited, a wholly owned subsidiary, was involved.
What type of transaction was announced?
The transaction announced was the closing of a previously disclosed acquisition of I-Mab Biopharma Hong Kong Limited.
Does the filing specify the financial terms of the acquisition?
No, the filing does not specify the financial terms or the value of the acquisition.
Is I-Mab Biopharma Hong Kong Limited a wholly owned subsidiary?
Yes, the filing states that I-Mab Biopharma Hong Kong Limited is a wholly owned subsidiary of I-Mab.
Filing Stats: 470 words · 2 min read · ~2 pages · Grade level 10.9 · Accepted 2025-10-28 16:01:02
Key Financial Figures
- $1.8 million — alth shareholders an upfront payment of $1.8 million and non-contingent payments of $1.2 mil
- $1.2 million — million and non-contingent payments of $1.2 million through 2027. In addition, Bridge Healt
- $3.875 m — eive future milestone payments of up to $3.875 million, subject to the achievement of ce
Filing Documents
- bridge_health_close_-_10.htm (6-K) — 28KB
- 0001193125-25-253456.txt ( ) — 29KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized. I-MAB By : /s/ Xi-Yong Fu Name : Xi-Yong (Sean) Fu Title : Chief Executive Officer Date: October 28, 2025